Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 800 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Research with integrity – the importance of communication November 14, 2022 An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer August 21, 2020 Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... November 3, 2025 Load more HOT NEWS Will Ponsegromab Be a Game Changer for Cancer Cachexia? Checking in on our Mental Health FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s...
